Autolus Therapeutics plc Increase (Decrease) in Prepaid Expense and Other Assets
Autolus Therapeutics plc (AUTL) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$82.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- Autolus Therapeutics plc increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$30.00K, a 100.62% decline year-over-year.
- Autolus Therapeutics plc increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$52.00K.
- Autolus Therapeutics plc increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $153.00K.
- Autolus Therapeutics plc increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$4.59M.
- Autolus Therapeutics plc increase (decrease) in prepaid expense and other assets for fiscal 2025 was $266.00K.
- Autolus Therapeutics plc increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$938.00K.
- Autolus Therapeutics plc increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$1.73M.
- Autolus Therapeutics plc increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$161.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$82.00K 10-Q · filed 2026-08-11 | $71.00K derived: sum of 3 quarters · filed 2026-08-11 | -$4.52M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$52.00K 10-Q · filed 2026-05-14 | $101.00K derived: sum of 2 quarters · filed 2026-05-14 | -$4.49M derived: sum of 3 quarters · filed 2026-05-14 | $330.00K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $153.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$4.43M derived: sum of 2 quarters · filed 2026-03-27 | $382.00K derived: sum of 3 quarters · filed 2026-08-11 | $266.00K 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | -$4.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $229.00K derived: sum of 2 quarters · filed 2026-08-11 | $113.00K 10-Q · filed 2025-11-12 | -$537.00K derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $4.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $4.70M 10-Q · filed 2026-08-11 | $4.05M derived: sum of 3 quarters · filed 2026-08-11 | $3.92M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | -$116.00K 10-Q · filed 2026-05-14 | -$766.00K derived: sum of 2 quarters · filed 2026-05-14 | -$895.00K derived: sum of 3 quarters · filed 2026-05-14 | -$977.00K derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | -$650.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$779.00K derived: sum of 2 quarters · filed 2026-03-27 | -$861.00K derived: sum of 3 quarters · filed 2026-03-27 | -$938.00K 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | -$129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$211.00K derived: sum of 2 quarters · filed 2025-11-12 | -$288.00K 10-Q · filed 2025-11-12 | -$82.00K derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | -$82.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$159.00K 10-Q · filed 2025-08-12 | $47.00K derived: sum of 3 quarters · filed 2025-08-12 | -$68.00K derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | -$77.00K 10-Q · filed 2025-05-08 | $129.00K derived: sum of 2 quarters · filed 2025-05-08 | $14.00K derived: sum of 3 quarters · filed 2025-05-08 | -$6.00K derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $206.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $91.00K derived: sum of 2 quarters · filed 2025-03-20 | $71.00K derived: sum of 3 quarters · filed 2025-03-20 | -$1.73M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | -$115.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$135.00K derived: sum of 2 quarters · filed 2024-11-12 | -$1.93M 10-Q · filed 2024-11-12 | -$1.79M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | -$20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.82M 10-Q · filed 2024-08-08 | -$1.68M derived: sum of 3 quarters · filed 2024-08-08 | |||||
| 2023-03-31 | -$1.80M 10-Q · filed 2024-05-17 | -$1.66M derived: sum of 2 quarters · filed 2024-05-17 | ||||||
| 2022-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$161.00K 10-K · filed 2024-03-21 | ||||||
| 2022-09-30 | -$301.00K 10-Q · filed 2023-11-09 | |||||||
| 2021-12-31 | -$503.00K 10-K · filed 2024-03-21 | |||||||
| 2021-03-31 | -$163.00K 6-K · filed 2021-05-06 | -$176.00K derived: sum of 2 quarters · filed 2023-03-07 | -$33.00K derived: sum of 3 quarters · filed 2023-03-07 | $2.24M derived: sum of 4 quarters · filed 2023-03-07 | ||||
| 2020-12-31 | -$13.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-07 | $130.00K derived: sum of 2 quarters · filed 2023-03-07 | $2.40M derived: sum of 3 quarters · filed 2023-03-07 | $2.64M 20-F · filed 2023-03-07 | ||||
| 2020-09-30 | $143.00K derived: 6-K 9 month − 6-K 6 month · filed 2020-11-05 | $2.42M derived: sum of 2 quarters · filed 2020-11-05 | $2.65M 6-K · filed 2020-11-05 | $2.65M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2020-06-30 | $2.27M derived: 6-K 6 month − 6-K 3 month · filed 2020-08-06 | $2.51M 6-K · filed 2020-08-06 | $2.51M derived: sum of 3 quarters · filed 2022-03-10 | $2.51M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2020-03-31 | $233.00K 6-K · filed 2021-05-06 | $233.00K derived: sum of 2 quarters · filed 2022-03-10 | $233.00K derived: sum of 3 quarters · filed 2022-03-10 | $233.00K derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2019-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2022-03-10 | $0.00 derived: sum of 2 quarters · filed 2022-03-10 | $0.00 derived: sum of 3 quarters · filed 2022-03-10 | $0.00 20-F · filed 2022-03-10 | $21.01M 20-F · filed 2020-03-03 | |||
| 2019-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2020-11-05 | $0.00 derived: sum of 2 quarters · filed 2020-11-05 | $0.00 6-K · filed 2020-11-05 | $15.84M 6-K · filed 2019-11-07 | $0.00 derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2019-06-30 | $0.00 derived: 6-K 6 month − 6-K 3 month · filed 2020-08-06 | $0.00 6-K · filed 2020-08-06 | $10.71M 6-K · filed 2019-08-08 | $0.00 derived: sum of 3 quarters · filed 2021-03-04 | -$4.86M derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2019-03-31 | $0.00 6-K · filed 2020-05-07 | $0.00 derived: sum of 2 quarters · filed 2021-03-04 | -$4.86M derived: sum of 3 quarters · filed 2021-03-04 | |||||
| 2018-12-31 | $0.00 20-F · filed 2021-03-04 | $3.52M 20-F · filed 2019-02-25 | -$4.86M derived: sum of 2 quarters · filed 2021-03-04 | |||||
| 2018-09-30 | -$4.86M derived: 20-F 9 month − 6-K 6 month · filed 2021-03-04 | $0.00 20-F · filed 2021-03-04 | $5.76M 6-K · filed 2019-11-07 | $7.13M 20-F · filed 2020-03-03 | ||||
| 2018-06-30 | $4.86M 6-K · filed 2019-08-08 | |||||||
| 2017-09-30 | $2.32M 20-F · filed 2020-03-03 | |||||||
| 2016-09-30 | $2.05M 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |